PhIII Olvi-Vec Platinum-doublet ChemotherapyBevacizumab Compatedw/PlatinumDoublet Chemo&Bevacizumab

Cancer
Krishnansu Tewari
A Randomized Phase III Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime Study)
Cervix
Other Female Genital
Ovary

Study Description

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer

Eligibility

-Women >18 years old

  • History of histologically confirmed (from prior treatment) non-resectable ovarian, fallopian tube or primary peritoneal cancer.

-High-grade serous [including malignant mixed Mullerian tumor (MMMT) with metastasis that contains high grade epithelial carcinoma; FIGO grades 2 and 3 allowed], endometrioid, or clear-cell ovarian cancer.

-History of thromboembolic event within the prior 3 months.

-Pregnant or breast-feeding women.

-Smallpox vaccination within 1 year of study therapy.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.